百利天恒：倫康依隆妥單抗兩項III期臨床完成首例入組

財中社

07/23

7月23日，百利天恒（688506）發布公告，公司自主研發的全球首創EGFR×HER3雙抗ADC倫康依隆妥單抗/宜澤康（BL-B01D1/iza-bren）兩項III期臨床試驗於近日分別完成首例受試者入組，涉及適應症為經內分泌治療失敗的晚期HR+HER2-乳腺癌和含鉑化療失敗的局部晚期或轉移性膽道癌。　　BL-B01D1是全球首個且唯一獲批上市的EGFR×HER3雙抗ADC，截至目前已在中國和美國...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/news/2653403937"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653403937\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653403937?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-07-23 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653403937","market":"sh","top_or_hot":-1,"title":"百利天恒：倫康依隆妥單抗兩項III期臨床完成首例入組","media":"財中社","content":"<div>\n<p>7月23日，百利天恒（688506）發布公告，公司自主研發的全球首創EGFR×HER3雙抗ADC倫康依隆妥單抗/宜澤康（BL-B01D1/iza-bren）兩項III期臨床試驗於近日分別完成首例受試者入組，涉及適應症為經內分泌治療失敗的晚期HR+HER2-乳腺癌和含鉑化療失敗的局部晚期或轉移性膽道癌。　　BL-B01D1是全球首個且唯一獲批上市的EGFR×HER3雙抗ADC，截至目前已在中國和美國...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202607233819152061.html\">網頁鏈接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百利天恒：倫康依隆妥單抗兩項III期臨床完成首例入組</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百利天恒：倫康依隆妥單抗兩項III期臨床完成首例入組\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">財中社</strong><span class=\"h-time small\">2026-07-23 20:00</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>7月23日，百利天恒（688506）發布公告，公司自主研發的全球首創EGFR×HER3雙抗ADC倫康依隆妥單抗/宜澤康（BL-B01D1/iza-bren）兩項III期臨床試驗於近日分別完成首例受試者入組，涉及適應症為經內分泌治療失敗的晚期HR+HER2-乳腺癌和含鉑化療失敗的局部晚期或轉移性膽道癌。　　BL-B01D1是全球首個且唯一獲批上市的EGFR×HER3雙抗ADC，截至目前已在中國和美國...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202607233819152061.html\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://finance.eastmoney.com/a/202607233819152061.html\">財中社</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4134","symbol_name":"信息科技諮詢與其它服務","start_time":0,"source_url":"http://finance.eastmoney.com/a/202607233819152061.html","article_id":"2653403937","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607233819152061.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2653403937","pubTimestamp":1784808000,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"7月23日，百利天恒（688506）發布公告，公司自主研發的全球首創EGFR×HER3雙抗ADC倫康依隆妥單抗/宜澤康（BL-B01D1/iza-bren）兩項III期臨床試驗於近日分別完成首例受試者入組，涉及適應症為經內分泌治療失敗的晚期HR+HER2-乳腺癌和含鉑化療失敗的局部晚期或轉移性膽道癌。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"91194":"临工重机股份有限公司（临时代码）","688506":"百利天恒","BK4134":"信息科技咨询与其它服务","BK0239":"医药制造","III":"信息服务"},"translate_title":"Baili Tianheng: Lunkang Irontuzumab completed the first enrollment in two phase III clinical trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"91194":1.5,"688506":1.5,"III":1.5,"02615":1.5},"content_text":"7月23日，百利天恒（688506）發布公告，公司自主研發的全球首創EGFR×HER3雙抗ADC倫康依隆妥單抗/宜澤康（BL-B01D1/iza-bren）兩項III期臨床試驗於近日分別完成首例受試者入組，涉及適應症為經內分泌治療失敗的晚期HR+HER2-乳腺癌和含鉑化療失敗的局部晚期或轉移性膽道癌。　　BL-B01D1是全球首個且唯一獲批上市的EGFR×HER3雙抗ADC，截至目前已在中國和美國開展40餘項針對多種腫瘤類型的臨床試驗，其中III期臨床研究（含II/III期）共20項。　　且該藥已有7項適應症被CDE納入突破性治療品種名單，2項適應症被納入優先審評品種名單，1項適應症被FDA納入突破性治療品種名單。複發性或轉移性鼻咽癌、食管癌2項適應症已獲NMPA上市批准，局部晚期或轉移性三陰乳腺癌的上市申請也已獲CDE受理。　　2026年一季度，百利天恒實現收入9459萬元，歸母淨利潤-7.75億元。（文章來源：財中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}